Drug intelligence / Profile preview

JNJ-26113100

Development stage: Discontinued
Lead developer: Johnson & Johnson Pharmaceutical Research & Development LLC
Modality: Small Molecules
Administration: Oral

Overview

JNJ-26113100 is an oral small molecule drug that was developed by Johnson & Johnson Pharmaceutical Research & Development for the treatment of moderate atopic dermatitis in adults. The drug reached Phase 2 clinical trials, where it was evaluated for safety and efficacy in a double-blind, randomized, placebo-controlled study involving multiple dosing regimens. Its mechanism of action remains unknown or undisclosed. Development was discontinued after Phase 2 trials, and the drug is not approved or marketed for any indication.

Beyond the preview

Go deeper on JNJ-26113100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-26113100.

Explore the full profile